Przedstawiamy wybór publikacji naukowych związanych z immunoterapią IOZK. Możesz użyć filtrów, aby dokonać wyboru według typów nowotworów i metod lub wprowadzić wyszukiwane hasła.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-06-14 / Br J Clin Pharmacol 2019 Aug;85(8):1670-1683https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-06-14 / Br J Clin Pharmacol 2019 Aug;85(8):1670-16832019-06-14 00:00:002023-03-07 12:45:44Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-06-10 / Cancer Med 2019 Jun;https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-06-10 / Cancer Med 2019 Jun;2019-06-10 00:00:002019-06-10 00:00:00Modulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-06-06 / Ther Apher Dial 2019 Jun;23(3):279-288https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-06-06 / Ther Apher Dial 2019 Jun;23(3):279-2882019-06-06 00:00:002019-06-06 00:00:00Phase I/II Pilot Study of Wilms‘ Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-06-01 / J Clin Oncol 37, 2019 (suppl; abstr 2639)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-06-01 / J Clin Oncol 37, 2019 (suppl; abstr 2639)2019-06-01 00:00:002019-06-01 00:00:00Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-05-29 / Front Oncol 2019;9:436https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-05-29 / Front Oncol 2019;9:4362019-05-29 00:00:002022-09-29 14:03:17STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-05-16 / 2019 May;19(1):460https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-05-16 / 2019 May;19(1):4602019-05-16 00:00:002020-10-05 10:19:52Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-05-14 / BMJ Open 2019 05;9(5):e026779https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-05-14 / BMJ Open 2019 05;9(5):e0267792019-05-14 00:00:002019-05-14 00:00:00Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-05-01 / Nat. Rev. Cancer 2019 05;19(5):271-282https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-05-01 / Nat. Rev. Cancer 2019 05;19(5):271-2822019-05-01 00:00:002019-05-01 00:00:00Targeting cancer vulnerabilities with high-dose vitamin C
Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach
Modulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro
Phase I/II Pilot Study of Wilms‘ Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer
A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.
Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.
Wstępne wyniki badania klinicznego fazy I z zastosowaniem autologicznej szczepionki przeciwnowotworowej z komórek dendrytycznych ukierunkowanej na HER2 u pacjentów z rakiem z przerzutami lub operowanym rakiem pęcherza moczowego wysokiego ryzyka (NCT01730118).
Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.
Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma.
Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.
Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.
Oparta na neoantygenach spersonalizowana szczepionka DC na raka płuc: aktualizacja badań translacyjnych.
Dynamika statusu immunologicznego u pacjentek z rakiem szyjki macicy otrzymujących kompleksowe leczenie szczepionką z komórek dendrytycznych.
Possible viral oncolysis by members of the Reoviridae and Paramyxoviridae families (an in vitro study).
A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).
Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
Whole-body hyperthermia in combination with systemic therapy in advanced solid malignancies
Targeting cancer vulnerabilities with high-dose vitamin C